Elsevier Inc.

SHERPA: Unknown

People

  1. Abu-Rustum
    Abu-Rustum
  2. Chi
    Chi
  3. Lee
    Lee
  4. Giralt
    Giralt
  5. Mulhall
    Mulhall
  6. Perales
    Perales
  7. Sonoda
    Sonoda
  8. Leitao
    Leitao
  9. Wu
    Wu
  10. Wolden
    Wolden

Groups

  1. Department of Medicine (4610)
  2. Surgery (3546)
  3. Survivorship Research (2658)
  4. Solid Tumor Oncology Division (2651)
  5. Radiation Oncology, Department of (2158)
  6. GSK Faculty (1937)
  7. Center for Hematologic Malignancies (1674)
  8. Hematologic Malignancies, Division of (1609)
  9. Gynecology Disease Management Team (1425)
  10. Sloan Kettering Institute Faculty (1413)
Search Within
Formats
  1. Journal Article (7386)
  2. Meeting Abstract (4694)
  3. Review (617)
  4. Book Section (538)
  5. Editorial (250)
  6. Conference Paper (138)
  7. Correspondence (92)
  8. Guidelines (82)
  9. Research Letter (29)
  10. Miscellaneous (15)
  11. Book Whole (14)
Groups
  1. Department of Medicine (4610)
  2. Surgery (3546)
  3. Survivorship Research (2658)
  4. Solid Tumor Oncology Division (2651)
  5. Radiation Oncology, Department of (2158)
  6. GSK Faculty (1937)

More Groups

People
  1. Nadeem Abu-Rustum (464)
  2. Dennis Chi (420)
  3. Nancy Lee (409)
  4. Michael Zelefsky (401)
  5. Sergio Giralt (384)
  6. John Mulhall (377)

More People

Years
  1. 2025 (240)
  2. 2024 (784)
  3. 2023 (762)
  4. 2022 (794)
  5. 2021 (723)
  6. 2020 (714)

More Years

Publications
  1. International Journal of Radiation Oncology, Biology, Physics (2610)
  2. Gynecologic Oncology (1197)
  3. Journal of Thoracic Oncology (967)
  4. Biology of Blood and Marrow Transplantation (815)
  5. European Journal of Cancer (524)
  6. Journal of Sexual Medicine (435)

More Publications

Results (13855)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Evidence-based definition of region of interest (ROI) for abdominal DIBH surface-guided radiotherapy
    Meeting Abstract

    Song, Y.; Zhai, X.; Liang, Y.; Zeng, C.; Mueller, B. A.; Li, G.
    International Journal of Radiation Oncology, Biology, Physics (2022)

    Fulltext@MSK | Save
  • Value-based cancer care: How are we training future radiation oncologists on the quality/cost equation?
    Meeting Abstract

    Bell, L.; Chino, F.
    International Journal of Radiation Oncology, Biology, Physics (2022)

    Fulltext@MSK | Save
  • CD19-directed chimeric antigen receptor T cell therapy in Waldenström macroglobulinemia: Initial experience in two clinical trials
    Meeting Abstract

    Qualls, D.; Monette, S.; Sethi, S.; Dogan, A.; Roshal, M.; Senechal, B.; Wang, X.; Riviere, I.; Sadelain, M.; Brentjens, R.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • CARTITUDE-1: Two-year post last patient in (LPI) results from the phase 1b/2 study of ciltacabtagene autoleucel (cilta-cel), a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T (CAR-T) cell therapy, in patients with relapsed/refractory multiple myeloma (RRMM)
    Meeting Abstract

    Usmani, S. Z.; Martin, T.; Berdeja, J. G.; Jakubowiak, A.; Agha, M.; Cohen, A. D.; Deol, A.; Htut, M.; Lesokhin, A.; Munshi, N. C.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • Exploring alternative dosing regimens of single-agent belantamab mafodotin on safety and efficacy in patients with relapsed or refractory multiple myeloma (RRMM): DREAMM-14
    Meeting Abstract

    Hultcrantz, M.; Kleinman, D.; Ghataorhe, P.; McKeown, A.; He, W.; Ling, T.; Jewell, R. C.; Byrne, J.; Eliason, L.; Scott, E.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • Interventions and outcomes of multiple myeloma patients progressing after BCMA-targeted chimeric antigen receptor (CAR) T-cell therapy
    Meeting Abstract

    Van Oekelen, O.; Nath, K.; Mouhieddine, T. H.; Farzana, T.; Aleman, A.; Melnekoff, D. T.; Ghodke-Puranik, Y.; Jagannath, S.; Shah, U. A.; Mailankody, S.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • Mosunetuzumab monotherapy is an effective and well-tolerated treatment option for patients with relapsed/refractory (R/R) follicular lymphoma (FL) who have received ≥2 prior lines of therapy: Pivotal results from a phase I/II study
    Meeting Abstract

    Budde, E. L.; Sehn, L. H.; Matasar, M.; Schuster, S. J.; Assouline, S.; Giri, P.; Kuruvilla, J.; Canales, M.; Dietrich, S.; Fay, K.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • Subcutaneous epcoritamab with rituximab + lenalidomide (R(2)) in patients with relapsed or refractory (R/R) follicular lymphoma (FL): Update from phase 1/2 trial
    Meeting Abstract

    Falchi, L.; Leppä, S.; Wahlin, B. E.; Nijland, M.; Christensen, J. H.; De Vos, S.; Holte, H.; Linton, K. M.; Abbas, A.; Wang, L. W.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • Pirtobrutinib, a highly selective, noncovalent (reversible) BTK inhibitor in previously treated mantle cell lymphoma: Updated results from the phase 1/2 BRUIN study
    Meeting Abstract

    Cohen, J. B.; Shah, N. N.; Alencar, A. J.; Gerson, J. N.; Patel, M. R.; Fakhri, B.; Jurczak, W.; Tan, X. N.; Lewis, K. L.; Fenske, T.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • Primary efficacy and safety analysis of a global phase II study of zandelisib administered by intermittent dosing (ID) in patients with relapsed or refractory (R/R) follicular lymphoma (FL): The TIDAL study
    Meeting Abstract

    Phillips, T.; Jurczak, W.; Ribrag, V.; Linton, K.; Collin, G. P.; Lopéz-Jimenéz, J.; Reddy, N.; Mengarelli, A.; Musuraca, G.; Sheehy, O.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save